Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 12, 2017. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| September 11, 2017 | Ordinary Shares (25 pence each) | £15.0052 | 16 Shares | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions under the Company's Share Reward Plan.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a statutory disclosure of share purchases by the following executives:
- Ms E Walmsley (Chief Executive Officer)
- Mr R G Connor (President, Global Manufacturing & Supply)
- Mr S Dingemans (Chief Financial Officer)
- Mr N Hirons (SVP, Global Ethics & Compliance)
- Mr D S Redfern (Chief Strategy Officer)
- Ms C Thomas (SVP, Human Resources)
- Mr P C Thomson (President, Global Affairs)
- Dr P J T Vallance (President, R&D)
- Mrs V A Whyte (Company Secretary)
Each executive acquired 8 partnership shares and 8 matching shares, totaling 16 shares per individual.
Investor Verification Checklist
- Verify the total number of shares acquired by each listed executive against the company's annual proxy statement or Form 20-F.
- Confirm the share price of £15.0052 aligns with the closing price on the London Stock Exchange for September 11, 2017.
- Review the terms of the Company's Share Reward Plan to understand the matching share mechanism.
- Note that this filing contains no operational or financial performance data; refer to the most recent Form 20-F for those metrics.